CLOV at a glance
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV, SEC CIK 1801170) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) reported revenue of $1.9 billion (up 40.3% from FY2024) and a net loss of $85.5 million.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) shares worth $453.5 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by THORNTON JOSEPH CLAY on November 16, 2026 of 22,099 shares at $4.97 per share.
- In the last 90 days, CLOV insiders reported 0 open-market purchases ($0) and 17 open-market sales ($3.8M) on Form 4, a net sale of $3.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.9B
- +40.3% vs prior year
- Insiders · 90 days
- 0 buys · 17 sells
- Net −$3.8M
- 13F holders
- 27 funds
- $453.5M · −3 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $759.3M, up 52.9% YoY, driven by 46% membership growth and 7% higher per-member premiums
- Net income $6.4M vs $24.4M loss YoY, adjusted EBITDA $16.1M vs $2.1M
- Insurance segment: premiums $748.8M, benefits expense ratio 91.1% vs 93.5% YoY
- Cash, equivalents and investments $512.6M vs $319.9M at December 31, 2025
- Operating cash flow $203.5M vs $1.2M YoY, with $73.1M investment purchases and $5.7M financing outflow
Risk Factors
- No material changes in risk factors from the 2025 Form 10-K
- Carried-forward risk: adverse events could materially harm business, financial condition, and results
- Market risk: risk events could cause Class A common stock price declines, potentially permanent
- Regulatory disclosure risk: future SEC filings may update currently disclosed risk factors
AI summary of the CLOV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Supplemental Q&A published following Clover Health’s third-quarter 2026 earnings announcement
- Responses address selected shareholder-submitted questions and provide additional investor context
Item EX-99.1: Item EX-99.1
- Management sees meaningful earnings leverage through 2028 as 2025-2026 cohorts, roughly half of membership, mature into stronger economics
- 3Q26 membership reached ~159k, leaving fixed-cost absorption potential and a stated 100-150 basis-point 2026 Adjusted SG&A improvement target
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results announcement for quarter ended September 30, 2026
- Full financial results and management commentary available in Exhibit 99.1
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Permanent CFO appointment effective November 4, 2026, ending interim status since March 30, 2026
- Thornton compensation: $450,000 base salary, bonus target up to 75% of base salary
Item EX-99.1: Item EX-99.1
- Q3 GAAP net income $6.4M, versus $(24.4)M loss, bringing nine-month profit to $61.8M
- Revenue $759.3M, up 52.9%, with Medicare Advantage membership up 46.3% to 158,383
Item 7.01: Regulation FD Disclosure
- 2027 CMS Star Ratings: 5 Stars for Clover’s PPO MA plans and 4.5 Stars for its HMO plan
- Ratings affect payment year 2028, supporting future Medicare Advantage reimbursement
Item EX-99.1: Item EX-99.1
- CMS awarded Clover’s PPO MA plans 5 Stars and HMO plan 4.5 Stars for 2027, affecting payment year 2028
- 5-Star PPO status enables year-round enrollment, supporting membership growth and improved acquisition flexibility
AI summaries of CLOV 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CLOV
Don't miss the next CLOV filing
- Alerts as it files. A push when CLOV files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CLOV, by share count.
- Ask anything. An AI agent that reads every CLOV filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| THORNTON JOSEPH CLAY | Sell | Nov 16, 2026 | 22,099 | $4.97 |
| THORNTON JOSEPH CLAY | A | Nov 4, 2026 | 328,947 | - |
| OLDAKOWSKI JOSEPH FRANK | A | Nov 4, 2026 | 186,403 | - |
| Soares Karen | Sell | Oct 20, 2026 | 19,275 | $4.66 |
| Reynoso Jamie L. | Sell | Oct 19, 2026 | 4,066 | $4.41 |
| Soares Karen | Sell | Oct 15, 2026 | 14,673 | $4.68 |
| THORNTON JOSEPH CLAY | Sell | Oct 15, 2026 | 4,591 | $4.68 |
| Wai Conrad | Sell | Oct 15, 2026 | 23,627 | $4.68 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $1.4B | $1.9B |
| Operating Income | - | -$45.7M | -$85.5M |
| Net Income | -$213.4M | -$43.0M | -$85.5M |
| Op. Margin | - | -3.3% | -4.4% |
| Net Margin | - | -3.1% | -4.4% |
| Balance Sheet | |||
| Total Assets | $570.7M | $580.7M | $541.0M |
| Equity | $286.4M | $341.1M | $308.7M |
| ROE | -74.5% | -12.6% | -27.7% |
| Per Share | |||
| EPS | $-0.44 | - | - |
| Cash Flow | |||
| Operating CF | -$115.9M | $34.8M | -$66.9M |
| CapEx | $584K | $1.6M | $2.0M |
Source: XBRL data in CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CLOV share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $453.5M |
| Q2 2026 | 30 | $497.9M |
| Q1 2026 | 29 | $153.8M |
| Q4 2025 | 26 | $218.0M |
| Q3 2025 | 30 | $283.0M |
| Q2 2025 | 28 | $283.9M |
| Q1 2025 | 20 | $205.4M |
| Q4 2024 | 16 | $142.9M |
- Vanguard Portfolio Management LLC+3.12M (+70%)
- D.E. Shaw & Co+2.42M (+123%)
- Renaissance Technologies LLC+1.75M (+62%)
- BlackRock+1.40M (+4%)
- Franklin Resources+721.9K (+336%)
- Millennium Management−877.3K (-79%)
- PNC Financial Services−699.9K (-20%)
- Wells Fargo & Co−251.0K (-64%)
- Morgan Stanley−222.4K (-10%)
- Citigroup−174.2K (-78%)
- Two Sigma Investments+32.5K
- Allstate+14.4K
- Blackstone Group−64.3K
- FMR LLC (Fidelity)−14.8K
- Truist Financial−10.4K
- Fifth Third Bancorp−6.5K
- Atlantic Union Bankshares Corp−35
Source: 13F-HR filings on SEC EDGAR (aggregated from 206 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CLOV filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 17, 2026 | - | - | - |
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 4 | Nov 6, 2026 | - | - | - |
| 4 | Nov 6, 2026 | - | - | - |
| 10-Q | Nov 6, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 4 | Oct 20, 2026 | - | - | - |
| 4 | Oct 20, 2026 | - | - | - |
| 4 | Oct 19, 2026 | - | - | - |
| 4 | Oct 19, 2026 | - | - | - |
| 4 | Oct 19, 2026 | - | - | - |
| 4 | Oct 19, 2026 | - | - | - |
| 4 | Oct 19, 2026 | - | - | - |
| 8-K | Oct 9, 2026 | - | Analysis | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 8-K | Sep 25, 2026 | - | Analysis | - |
| 8-K | Sep 24, 2026 | - | Analysis | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
Related Health Care companies
- ALHC · Alignment Healthcare, Inc.Hospital & Medical Service Plans
- CNC · Centene CorporationHospital & Medical Service Plans
- CI · CignaHospital & Medical Service Plans
- ELV · Elevance HealthHospital & Medical Service Plans
- HUM · HumanaHospital & Medical Service Plans
- MOH · Molina HealthcareHospital & Medical Service Plans
- OSCR · Oscar Health, Inc.Hospital & Medical Service Plans
- TRUP · TRUPANION, INC.Hospital & Medical Service Plans
CLOV SEC filings: frequently asked questions
Are CLOV insiders buying or selling?
In the last 90 days, CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) officers, directors and 10% owners reported no open-market purchases and 17 open-market sales worth $3.8 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CLOV stock?
As of September 30, 2026, the largest CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) holders among the 13F filers tracked by SignalX were BlackRock ($157.4 million), Vanguard Capital Management LLC ($79.2 million), State Street Corp ($46.1 million), Vanguard Portfolio Management LLC ($32.7 million), Renaissance Technologies LLC ($19.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CLOV's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) reported revenue of $1.9 billion (up 40.3% from FY2024) and a net loss of $85.5 million. The figures come from the XBRL data in the 10-K.
What did CLOV report in its latest 8-K?
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure). Supplemental Q&A published following Clover Health’s third-quarter 2026 earnings announcement.
What are the latest CLOV SEC filings?
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 17, 2026.
What is CLOV's SEC CIK number?
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)'s SEC Central Index Key (CIK) is 1801170. EDGAR lists every CLOV filing under that number.
Ask anything about CLOV
The research agent reads CLOV's filings, financials, insider trades and 13F holders, then answers with sources.